You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Johnson and Johnson
Dow
Baxter
Harvard Business School

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 8,633,201

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,633,201
Title:Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
Inventor(s): Aicher; Babette (Frankfurt am Main, DE), Coulter; Thomas Stephen (Wantage, GB), Jaekel; Stefan (Darmstadt, DE), Kelter; Arndt-Rene (Alfter, DE), Murfin; Stephen (Didcot, GB), Reuter; Tanja (Darmstadt, DE), Taylor; Steven (Didcot, GB)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:12/296,427
Patent Claims:see list of patent claims

Details for Patent 8,633,201

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Lilly HUMULIN R insulin recombinant human INJECTABLE;INJECTION 018780 001 1982-12-02   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2026-04-07 RX search
Lilly HUMULIN R KWIKPEN insulin human SOLUTION;SUBCUTANEOUS 018780 002 1982-12-02   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2026-04-07 RX search
Lilly HUMULIN R insulin human SOLUTION;SUBCUTANEOUS 018780 004 1982-12-02   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2026-04-07 RX search
Lilly HUMULIN R PEN insulin recombinant human INJECTABLE;INJECTION 018780 005 1982-12-02   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2026-04-07 RX search
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2026-04-07 RX search
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2026-04-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Johnson and Johnson
Harvard Business School
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.